Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of diseases with high unmet medical needs. Our hope and vision is to build transformative, life-changing medicines for patients and their families.
Our team has extensive experience in the discovery and development of RNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely positions us to catalyze the next generation of RNA medicines.
October 2, 2019
Arcturus Therapeutics to Present at Three Upcoming Investor Conferences
September 26, 2019
Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock
September 23, 2019
Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors